FDA — authorised 10 June 2011
- Application: NDA022345
- Marketing authorisation holder: GLAXOSMITHKLINE
- Local brand name: POTIGA
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 Retigabine in United States
FDA authorised Retigabine on 10 June 2011
Marketing authorisation
Retigabine in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in United States
Frequently asked questions
Is Retigabine approved in United States?
Yes. FDA authorised it on 10 June 2011.
Who is the marketing authorisation holder for Retigabine in United States?
GLAXOSMITHKLINE holds the US marketing authorisation.